FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication
Naún Lobo-Galo, Manuel Terrazas-López, Alejandro Martı́nez-Martı́nez, Ángel G. Díaz‐Sánchez
Abstract
, it is not recommended anti-COVID-19 therapy, due to the fact that it can induce the expression of the viral cellular receptor such as, angiotensin-converting enzyme ACE-2, and thus, making the patient potentially more susceptible to infection. On the other hand, disulfiram, an alcoholism-averting drug, has been previously proposed as an antimicrobial and anti-SARS and MERS agent, safe to use even at higher doses with low side effects, it is recommended to be tested for control of SARS-CoV-2 infection.Communicated by Ramaswamy H. Sarma.
Topics & Concepts
DisulfiramViral replicationPharmacologyProteaseDrugPopulationPolyproteinsVirologyFavipiravirMedicineVirusEnzymeChemistryCoronavirus disease 2019 (COVID-19)BiochemistryDiseaseEnvironmental healthInfectious disease (medical specialty)PathologySARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery MethodsEndoplasmic Reticulum Stress and Disease